Scotland Rejects Lecanemab for NHS Coverage, Citing Cost and Benefit Uncertainties
Key Insights
The Scottish Medicines Consortium (search) (SMC) has denied NHS coverage for lecanemab (Leqembi), an Alzheimer's (search) treatment, citing concerns over cost-benefit ratio and implementation challenges.
The decision follows similar rejections by NICE for England and Wales, leaving the £60,000-per-year treatment available only through private clinics in the UK.
Healthcare experts warn that without government action, the UK risks falling behind other regions in providing access to innovative dementia treatments, with 30 potential new therapies expected by 2030.
The Scottish Medicines Consortium (search) (SMC) has announced its decision to reject lecanemab (Leqembi) for use within NHS Scotland, dealing another blow to Alzheimer's (search) patients seeking access to innovative treatments. The decision centers on uncertainties surrounding the drug's health benefits when weighed against its substantial costs, including expenses related to monthly infusions and ongoing safety monitoring.
The rejection mirrors the stance taken by the National Institute for Health and Care Excellence (NICE) six months ago for England and Wales, effectively limiting access to the drug across the UK. Currently, the treatment carries a price tag of £60,000 per year and is only available through private clinics in England.
Impact on Patients and Caregivers
The decision has sparked concern among patient advocacy groups, who describe it as a devastating setback for families already struggling with the challenges of dementia care. The financial burden is particularly significant, considering that only 18% of dementia caregivers maintain paid employment, often having to leave their careers to support affected family members.
Hilary Evans-Newton, Chief Executive of Alzheimer's Research UK (search), emphasized the broader implications of this decision: "Without action, the NHS risks progressively falling further behind Europe, America and Asia when it comes to access to new, innovative dementia treatments – many more of which are on the horizon."
Infrastructure and Implementation Challenges
The rejection largely stems from practical implementation challenges, including the need for expanded diagnostic infrastructure and resources for administering regular infusions. However, potential solutions are being explored, including the possibility of transitioning from hospital-based infusions to home injections – an approach currently under FDA review in the United States.
Future Outlook and Potential Solutions
The global pipeline for Alzheimer's (search) treatments remains robust, with over 160 ongoing trials testing more than 125 experimental treatments. Notably, NHS England has identified 30 potential treatments that could be available by 2030, highlighting the urgent need for systematic changes to accommodate emerging therapies.
The SMC has indicated openness to reconsidering their decision, stating they would "welcome a resubmission from the company with changes to address the uncertainties." This leaves room for potential future access, particularly if concerns about cost-effectiveness and implementation can be addressed.
Evans-Newton called for immediate action from stakeholders: "It's vital for the UK government, NHS leaders, and industry to come together and find innovative approaches to ensure people can benefit from new Alzheimer's (search) treatments now." She emphasized that the upcoming 10-Year Plan for Health must prioritize dementia care and treatment access to prevent further delays in adopting innovative therapies.